Кардиоваскулярные осложнения противоопухолевой терапии рака молочной железы: диагностика, профилактика и лечение

Автор: Потиевская Вера Исааковна, Ахобеков Альберт Амалиевич, Болотина Л.В., Королева Людмила Алексеевна, Каприн Андрей Дмитриевич

Журнал: Сибирский онкологический журнал @siboncoj

Рубрика: Обзоры

Статья в выпуске: 5 т.20, 2021 года.

Бесплатный доступ

Наряду со значительными успехами в лечении рака молочной железы, позволившими улучшить выживаемость, сердечно-сосудистые заболевания стали основной причиной инвалидизации и смертности, не связанной с рецидивом злокачественного новообразования. В общей популяции сердечно-сосудистые заболевания являются основной причиной смертности как у женщин, так и у мужчин. У пациенток с раком молочной железы частота сердечно-сосудистых заболеваний еще выше, чем в общей популяции. Высокая частота сердечно-сосудистых заболеваний у пациенток с раком молочной железы, вероятно, обусловлена наличием общих факторов риска, а также кардиотоксичностью противоопухолевой терапии. Рост развития сердечно-сосудистых заболеваний у выживших пациенток с раком молочной железы является серьезной проблемой. В данном обзоре литературы описаны частота встречаемости сердечно-сосудистых осложнений при разных схемах лечения рака молочной железы, факторы риска их развития, стратегии мониторинга функции сердечно-сосудистой системы во время и после противоопухолевой терапии, а также стратегии профилактики и лечения кардиотоксичности.

Еще

Рак молочной железы, противоопухолевая терапия, кардиотоксичность, сердечно-сосудистые заболевания

Короткий адрес: https://sciup.org/140261331

IDR: 140261331 | DOI: 10.21294/1814-4861-2021-20-5-138-148

Список литературы Кардиоваскулярные осложнения противоопухолевой терапии рака молочной железы: диагностика, профилактика и лечение

Bradshaw P.T., Stevens J., Khankari N., Teitelbaum S.L., Neugut A.I., Gammon M.D. Cardiovascular Disease Mortality Among Breast Cancer Survivors. Epidemiology. 2016 Jan; 27(1): 6-13. https://doi.org/10.1097/EDE.0000000000000394.
Park N.J., Chang Y., Bender C., Conley Y., Chlebowski R.T., van Londen G.J., Foraker R., Wassertheil-Smoller S., Stefanick M.L., Kuller L.H. Cardiovascular disease and mortality after breast cancer in postmenopausal women: Results from the Women’s Health Initiative. PLoS One. 2017 Sep 21; 12(9): e0184174. https://doi.org/10.1371/journal.pone.0184174.
Polk A., Shahmarvand N., Vistisen K., Vaage-Nilsen M., Larsen F.O., Schou M., Nielsen D.L. Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer. BMJ Open. 2016 Oct 19; 6(10): e012798. https://doi.org/10.1136/bmjopen-2016-012798.
National Cancer Institute Surveillance, Epidemiology and End Results Program (SEER). Cancer Stat Facts: Female Breast Cancer [Internet]. URL: https://seer.cancer.gov/statfacts/html/breast.html (cited 9.10.2018).
Zhang S., Liu X., Bawa-Khalfe T., Lu L.S., Lyu Y.L., Liu L.F., Yeh E.T. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012 Nov; 18(11): 1639-42. https://doi.org/10.1038/nm.2919.
Narayan H.K., Finkelman B., French B., Plappert T., Hyman D., Smith A.M., Margulies K.B., Ky B. Detailed Echocardiographic Phenotyping in Breast Cancer Patients: Associations With Ejection Fraction Decline, Recovery, and Heart Failure Symptoms Over 3 Years of Follow-Up. Circulation. 2017 Apr 11; 135(15): 1397-1412. https://doi.org/10.1161/CIRCULATIONAHA.116.023463.
Kotamraju S., Chitambar C.R., Kalivendi S.V., Joseph J., Kalyanaraman B. Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: role of oxidantinduced iron signaling in apoptosis. J Biol Chem. 2002 May 10; 277(19): 17179-87. https://doi.org/10.1074/jbc.M111604200.
Kersting G., Tzvetkov M.V., Huse K., Kulle B., Hafner V., Brockmöller J., Wojnowski L. Topoisomerase II beta expression level correlates with doxorubicin-induced apoptosis in peripheral blood cells. Naunyn Schmiedebergs Arch Pharmacol. 2006; 374(1): 21-30. https://doi.org/10.1007/s00210-006-0091-0.
Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003 Jun 1; 97(11): 2869-79. https://doi.org/10.1002/cncr.11407.
Mackey J.R., Martin M., Pienkowski T., Rolski J., Guastalla J.P., Sami A., Glaspy J., Juhos E., Wardley A., Fornander T., Hainsworth J., Coleman R., Modiano M.R., Vinholes J., Pinter T., Rodríguez-Lescure A., Colwell B., Whitlock P., Provencher L., Laing K., Walde D., Price C., Hugh J.C., Childs B.H., Bassi K., Lindsay M.A., Wilson V., Rupin M., Houé V., Vogel C.; TRIO/BCIRG 001 investigators. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013 Jan; 14(1): 72-80. https://doi.org/10.1016/S1470-2045(12)70525-9.
Bonneterre J., Roché H., Kerbrat P., Fumoleau P., Goudier M.J., Fargeot P., Montcuquet P., Clavère P., Barats J.C., Monnier A., Veyret C., Datchary J., Van Praagh I., Chapelle-Marcillac I. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol. 2004 Aug 1; 22(15): 3070-9. https://doi.org/10.1200/JCO.2004.03.098.
Pinder M.C., Duan Z., Goodwin J.S., Hortobagyi G.N., Giordano S.H. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007; 25(25): 3808-15. https://doi.org/10.1200/JCO.2006.10.4976.
Vejpongsa P., Yeh E.T. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014 Sep 2; 64(9): 938-45. https://doi.org/10.1016/j.jacc.2014.06.1167.
Marty M., Espié M., Llombart A., Monnier A., Rapoport B.L., Stahalova V.; Dexrazoxane Study Group. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracyclinebased chemotherapy. Ann Oncol. 2006 Apr; 17(4): 614-22. https://doi.org/10.1093/annonc/mdj134.
Swain S.M., Whaley F.S., Gerber M.C., Weisberg S., York M., Spicer D., Jones S.E., Wadler S., Desai A., Vogel C., Speyer J., Mittelman A., Reddy S., Pendergrass K., Velez-Garcia E., Ewer M.S., Bianchine J.R., Gams R.A. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997 Apr; 15(4): 1318-32. https://doi.org/10.1200/JCO.1997.15.4.1318.
Venturini M., Michelotti A., Del Mastro L., Gallo L., Carnino F., Garrone O., Tibaldi C., Molea N., Bellina R.C., Pronzato P., Cyrus P., Vinke J., Testore F., Guelfi M., Lionetto R., Bruzzi P., Conte P.F., Rosso R. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol. 1996; 14(12): 3112-20. https://doi.org/10.1200/JCO.1996.14.12.3112.
Lopez M., Vici P., Di Lauro K., Conti F., Paoletti G., Ferraironi A., Sciuto R., Giannarelli D., Maini C.L. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol. 1998; 16(1): 86-92. https://doi.org/10.1200/JCO.1998.16.1.86.
HERCEPTIN (trastuzumab). Highlights of Prescribing Information, Genentech, Inc., San Francisco, CA, October 2010. [Internet] URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf (9.10.2018).
Florido R., Smith K.L., Cuomo K.K., Russell S.D. Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. J Am Heart Assoc. 2017 Sep 22; 6(9): e006915. https://doi.org/10.1161/JAHA.117.006915.
Onitilo A.A., Engel J.M., Stankowski R.V. Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Ther Adv Drug Saf. 2014; 5(4): 154-66. https://doi.org/10.1177/2042098614529603.
Yu A.F., Yadav N.U., Manrique C.R., Thaler H.T., Hudis C.A., Dang C.T., Steingart R.M. Impact of trastuzumab-induced cardiotoxicity and subsequent trastuzumab interruption on breast cancer outcome. Circulation. 2013; 128: A9317.
Lynce F., Barac A., Geng X., Dang C., Yu A.F., Smith K.L., Gallagher C., Pohlmann P.R., Nunes R., Herbolsheimer P., Warren R., Srichai M.B., Hofmeyer M., Cunningham A., Timothee P., Asch F.M., Shajahan-Haq A., Tan M.T., Isaacs C., Swain S.M. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2- positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat. 2019 Jun; 175(3): 595-603. https://doi.org/10.1007/s10549-019-05191-2.
Mantarro S., Rossi M., Bonifazi M., D'Amico R., Blandizzi C., La Vecchia C., Negri E., Moja L. Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer. Intern Emerg Med. 2016 Feb; 11(1): 123-40. https://doi.org/10.1007/s11739-015-1362-x.
Ky B., Putt M., Sawaya H., French B., Januzzi J.L.Jr., Sebag I.A., Plana J.C., Cohen V., Banchs J., Carver J.R., Wiegers S.E., Martin R.P., Picard M.H., Gerszten R.E., Halpern E.F., Passeri J., Kuter I., ScherrerCrosbie M. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014 Mar 4; 63(8): 809-16. https://doi.org/10.1016/j.jacc.2013.10.061.
Mohan N., Jiang J., Dokmanovic M., Wu W.J. Trastuzumabmediated cardiotoxicity: current understanding, challenges, and frontiers. Antib Ther. 2018 Aug 31; 1(1): 13-17. https://doi.org/10.1093/abt/tby003.
Zamorano J.L., Lancellotti P., Rodriguez Muñoz D., Aboyans V., Asteggiano R., Galderisi M., Habib G., Lenihan D.J., Lip G.Y.H., Lyon A.R., Lopez Fernandez T., Mohty D., Piepoli M.F., Tamargo J., Torbicki A., Suter T.M.; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016 Sep 21; 37(36): 2768-2801. https://doi.org/10.1093/eurheartj/ehw211.
Cardinale D., Colombo A., Lamantia G., Colombo N., Civelli M., De Giacomi G., Rubino M., Veglia F., Fiorentini C., Cipolla C.M. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010 Jan; 55(3): 213-20. https://doi.org/10.1016/j.jacc.2009.03.095.
Earl H.M., Hiller L., Vallier A.L., Loi S., Howe D., Higgins H.B., PERSEPHONE Trial Investigators. PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. J Clin Oncol. 2018; 36(15): 506.
Sendur M.A., Aksoy S., Altundag K. Cardiotoxicity of novel HER2- targeted therapies. Curr Med Res Opin. 2013 Aug; 29(8): 1015-24. https://doi.org/10.1185/03007995.2013.807232.
SABCS 2019 [Internet]. URL: https://www.practiceupdate.com/content/sabcs-2019-recommendations-from-dr-sara-tolaney/93466 (cited 23.02.2020).
Pai V.B., Nahata M.C. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000 Apr; 22(4): 263-302. https://doi.org/10.2165/00002018-200022040-00002.
Khosrow-Khavar F., Filion K.B., Al-Qurashi S., Torabi N., Bouganim N., Suissa S., Azoulay L. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2017 Mar 1; 28(3): 487-496. https://doi.org/10.1093/annonc/mdw673.
Cardoso F., Senkus E., Costa A., Papadopoulos E., Aapro M., André F., Harbeck N., Aguilar Lopez B., Barrios C.H., Bergh J., Biganzoli L., Boers-Doets C.B., Cardoso M.J., Carey L.A., Cortés J., Curigliano G., Diéras V., El Saghir N.S., Eniu A., Fallowfield L., Francis P.A., Gelmon K., Johnston S.R.D., Kaufman B., Koppikar S., Krop I.E., Mayer M., Nakigudde G., Offersen B.V., Ohno S., Pagani O., Paluch-Shimon S., Penault-Llorca F., Prat A., Rugo H.S., Sledge G.W., Spence D., Thomssen C., Vorobiof D.A., Xu B., Norton L., Winer E.P. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol. 2018; 29(8): 1634-57. https://doi.org/10.1093/annonc/mdy192.
Slamon D.J., Neven P., Chia S., Fasching P.A., De Laurentiis M., Im S.A., Petrakova K., Bianchi G.V., Esteva F.J., Martín M., Nusch A., Sonke G.S., De la Cruz-Merino L., Beck J.T., Pivot X., Vidam G., Wang Y., Rodriguez Lorenc K., Miller M., Taran T., Jerusalem G. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018; 36(24): 2465 2472. https://doi.org/10.1200/JCO.2018.78.9909.
Lilly’s Verzenio® (abemaciclib) significantly extended life in women with HR+, HER2- advanced breast cancer in MONARCH-2. July 30, 2019 [Internet]. URL: https://investor.lilly.com/news-releases/news-release-details/lillys-verzenior-abemaciclib-significantly-extendedlife-women (cited 23.02.2020).
Sledge G.W.Jr., Toi M., Neven P., Sohn J., Inoue K., Pivot X., Burdaeva O., Okera M., Masuda N., Kaufman P.A., Koh H., Grischke E.M., Frenzel M., Lin Y., Barriga S., Smith I.C., Bourayou N., Llombart-Cussac A. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017 Sep 1; 35(25): 2875- 2884. https://doi.org/10.1200/JCO.2017.73.7585.
Tripathy D., Im S.A., Colleoni M., Franke F., Bardia A., Harbeck N., Hurvitz S.A., Chow L., Sohn J., Lee K.S., Campos-Gomez S., Villanueva Vazquez R., Jung K.H., Babu K.G., Wheatley-Price P., De Laurentiis M., Im Y.H., Kuemmel S., El-Saghir N., Liu M.C., Carlson G., Hughes G., DiazPadilla I., Germa C., Hirawat S., Lu Y.S. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018 Jul; 19(7): 904-915. https://doi.org/10.1016/S1470-2045(18)30292-4.
Im S.A., Lu Y.S., Bardia A., Harbeck N., Colleoni M., Franke F., Chow L., Sohn J., Lee K.S., Campos-Gomez S., Villanueva-Vazquez R., Jung K.H., Chakravartty A., Hughes G., Gounaris I., Rodriguez-Lorenc K., Taran T., Hurvitz S., Tripathy D. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019 Jul 25; 381(4): 307-316. https://doi.org/10.1056/NEJMoa1903765.
Ministerstvo zdravookhraneniya Rossiiskoi Federatsii. Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata RISARG LP-004670. 30 c.
Durairaj C., Ruiz-Garcia A., Gauthier E.R., Huang X., Lu D.R., Hoffman J.T., Finn R.S., Joy A.A., Ettl J., Rugo H.S., Zheng J., Wilner K.D., Wang D.D. Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anticancer Drugs. 2018 Mar; 29(3): 271-280. https://doi.org/10.1097/CAD.0000000000000589.
Wang T.J., Evans J.C., Benjamin E.J., Levy D., LeRoy E.C., Vasan R.S. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003; 108(8): 977-82. https://doi.org/10.1161/01.CIR.0000085166.44904.79.
SOLVD Investigators, Yusuf S., Pitt B., Davis C.E., Hood W.B.Jr., Cohn J.N. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992 Sep 3; 327(10): 685-91. https://doi.org/10.1056/NEJM199209033271003.
Pfeffer M.A., McMurray J.J., Velazquez E.J., Rouleau J.L., Køber L., Maggioni A.P., Solomon S.D., Swedberg K., Van de Werf F., White H., Leimberger J.D., Henis M., Edwards S., Zelenkofske S., Sellers M.A., Califf R.M.; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003 Nov 13; 349(20): 1893-906. https://doi.org/10.1056/NEJMoa032292.
Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E.Jr., Colvin M.M., Drazner M.H., Filippatos G.S., Fonarow G.C., Givertz M.M., Hollenberg S.M., Lindenfeld J., Masoudi F.A., McBride P.E., Peterson P.N., Stevenson L.W., Westlake C. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017 Aug 8; 136(6): e137-e161. https://doi.org/10.1161/CIR.0000000000000509.
Lipshultz S.E., Lipsitz S.R., Sallan S.E., Simbre V.C.2nd, Shaikh S.L., Mone S.M., Gelber R.D., Colan S.D. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002 Dec 1; 20(23): 4517-22. https://doi.org/10.1200/JCO.2002.12.102.
Herrmann J., Lerman A., Sandhu N.P., Villarraga H.R., Mulvagh S.L., Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014 Sep; 89(9): 1287-306. https://doi.org/10.1016/j.mayocp.2014.05.013.
Cardinale D., Sandri M.T., Colombo A., Colombo N., Boeri M., Lamantia G., Civelli M., Peccatori F., Martinelli G., Fiorentini C., Cipolla C.M. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004 Jun 8; 109(22): 2749-54. https://doi.org/10.1161/01.CIR.0000130926.51766.CC.
Ky B., Putt M., Sawaya H., French B., Januzzi J.L.Jr., Sebag I.A., Plana J.C., Cohen V., Banchs J., Carver J.R., Wiegers S.E., Martin R.P., Picard M.H., Gerszten R.E., Halpern E.F., Passeri J., Kuter I., ScherrerCrosbie M. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014 Mar 4; 63(8): 809-16. https://doi.org/10.1016/j.jacc.2013.10.061.
Ledwidge M., Gallagher J., Conlon C., Tallon E., O'Connell E., Dawkins I., Watson C., O'Hanlon R., Bermingham M., Patle A., Badabhagni M.R., Murtagh G., Voon V., Tilson L., Barry M., McDonald L., Maurer B., McDonald K. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013 Jul 3; 310(1): 66-74. https://doi.org/10.1001/jama.2013.7588.
Armenian S.H., Lacchetti C., Lenihan D. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2017 Apr; 13(4): 270-275. https://doi.org/10.1200/JOP.2016.018770.
Thavendiranathan P., Poulin F., Lim K.D., Plana J.C., Woo A., Marwick T.H. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014 Jul 1; 63(25 Pt A): 2751-68. https://doi.org/10.1016/j.jacc.2014.01.073.
Cardinale D., Colombo A., Sandri M.T., Lamantia G., Colombo N., Civelli M., Martinelli G., Veglia F., Fiorentini C., Cipolla C.M. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006 Dec 5; 114(23): 2474-81. https://doi.org/10.1161/CIRCULATIONAHA.106.635144.
Gulati G., Heck S.L., Ree A.H., Hoffmann P., Schulz-Menger J., Fagerland M.W., Gravdehaug B., von Knobelsdorff-Brenkenhoff F., Bratland Å., Storås T.H., Hagve T.A., Røsjø H., Steine .K, Geisler J., Omland T. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016 Jun 1; 37(21): 1671-80. https://doi.org/10.1093/eurheartj/ehw022.
Pituskin E., Mackey J.R., Koshman S., Jassal D., Pitz M., Haykowsky M.J., Pagano J.J., Chow K., Thompson R.B., Vos L.J., Ghosh S., Oudit G.Y., Ezekowitz J.A., Paterson D.I. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of TrastuzumabAssociated Cardiotoxicity. J Clin Oncol. 2017 Mar 10; 35(8): 870-877. https://doi.org/10.1200/JCO.2016.68.7830.
Seicean S., Seicean A., Plana J.C., Budd G.T., Marwick T.H. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. 2012; 60(23): 2384-90. https://doi.org/10.1016/j. jacc.2012.07.067.
Acar Z., Kale A., Turgut M., Demircan S., Durna K., Demir S., Meriç M., Ağaç M.T. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011 Aug 23; 58(9): 988-9. https://doi.org/10.1016/j.jacc.2011.05.025.
Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E.Jr., Drazner M.H., Fonarow G.C., Geraci S.A., Horwich T., Januzzi J.L., Johnson M.R., Kasper E.K., Levy W.C., Masoudi F.A., McBride P.E., Mc- Murray J.J., Mitchell J.E., Peterson P.N., Riegel B., Sam F., Stevenson L.W., Tang W.H., Tsai E.J., Wilkoff B.L.; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15; 62(16): e147-239. https://doi.org/10.1016/j.jacc.2013.05.019.
Matskeplishvili S.T., Potievskaya V.I., Popovkina O.E., Bolotina L.V., Shklyaeva A.V., Poluektova M.V., Kaprin A.D. Serdechnososudistye oslozhneniya pri lechenii onkologicheskikh zabolevanii (kardioonkologiya): profilaktika, diagnostika, lechenie - soglasovannoe mnenie ekspertov. Tekhnologii zhivykh sistem. 2018; 15(6): 3-35.
Plokhova E.V., Dundua D.P. Osnovnye printsipy profilaktiki i lecheniya kardiotoksichnosti na fone khimioterapii u onkologicheskikh patsientov. Klinicheskaya praktika. 2019; 10(1): 31-41.

Еще

Статья обзорная